Heart failure drug combo aims to cut hospital stays
NCT ID NCT07351864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding finerenone to standard heart failure treatment (an SGLT2 inhibitor) can reduce deaths and hospitalizations. About 60 adults aged 18-65 with newly diagnosed heart failure will be split into two groups: one gets the standard drug alone, the other gets both drugs. Researchers will track heart-related deaths, hospital stays, and side effects like potassium levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mansoura University Hospitals, Cardiology Department (Specialized Medical Hospital)
Al Mansurah, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?